Hemophilia nursing: care guide for hemophilia A and B

Hemophilia A and B are X-linked recessive bleeding disorders caused by deficiencies of specific coagulation factors — factor VIII in hemophilia A and factor IX in hemophilia B. Both disrupt the intrinsic coagulation pathway, impairing thrombin generation and producing a clinical picture dominated by prolonged, deep-tissue bleeding and hemarthrosis. Severity is classified by residual factor activity. Nursing management centers on bleeding precautions, factor replacement, joint protection, and extensive patient education for self-management at home.

Definitions and inheritance

Hemophilia A is caused by a deficiency or dysfunction of factor VIII (antihemophilic factor). It is the most common severe inherited bleeding disorder, affecting approximately 1 in 5,000 male births. Roughly 60% of cases are caused by an inversion of intron 22 of the F8 gene; the remainder arise from point mutations, deletions, and duplications.

Hemophilia B — also called Christmas disease — is caused by a deficiency of factor IX. It is less common, affecting approximately 1 in 25,000 male births. The condition is named after Stephen Christmas, the first patient described in the 1952 British Medical Journal report.

Both disorders follow X-linked recessive inheritance:

• Males (XY) have only one X chromosome. A single defective allele produces clinical hemophilia.
• Females (XX) with one defective allele are carriers — they typically have ~50% factor activity and are usually asymptomatic, though some carrier females have factor levels low enough to cause mild bleeding (lyonization).
• A carrier female has a 50% chance of passing the defective allele to a son (who will have hemophilia) or a daughter (who will be a carrier).
• About 30% of hemophilia cases arise from new mutations with no family history.

The clinical presentation of hemophilia A and B is clinically indistinguishable. Specific factor assays are required to differentiate the two conditions.

Severity classification

Factor activity level determines clinical severity and guides treatment decisions. This classification applies equally to hemophilia A and B.

Approximately 60% of hemophilia A cases and 50% of hemophilia B cases are classified as severe. Severity does not change over a patient’s lifetime — a patient born with severe hemophilia does not “improve” to moderate disease.

Pathophysiology

Understanding where factors VIII and IX fit in the coagulation cascade is essential for interpreting hemophilia’s clinical and laboratory features.

The coagulation cascade: intrinsic pathway focus

Hemostasis involves two intersecting pathways — extrinsic (tissue factor–driven) and intrinsic (contact activation–driven) — that converge at factor X to form the common pathway, ultimately generating thrombin and a stable fibrin clot.

Factors VIII and IX operate within the intrinsic pathway (tenase complex):

1. Injury exposes subendothelial collagen, activating factor XII → XI → IX sequentially.
2. Activated factor IX (IXa) combines with factor VIIIa (its essential cofactor), calcium, and phospholipid to form the intrinsic tenase complex on the surface of activated platelets.
3. The tenase complex activates factor X to factor Xa with high efficiency — this is the amplification step that drives robust thrombin generation.
4. Factor Xa then combines with factor Va (the prothrombinase complex) to convert prothrombin to thrombin.
5. Thrombin converts fibrinogen to fibrin, cross-links fibrin via factor XIII, and amplifies platelet activation.

In hemophilia A or B, the tenase complex cannot assemble efficiently. Without adequate factor VIII or IX:

• Factor X activation is severely impaired
• Thrombin generation is grossly inadequate
• The platelet plug that forms initially (primary hemostasis) is not reinforced by a stable fibrin clot
• Bleeding continues — often for hours to days — particularly from deeper tissues where mechanical compression cannot control it

The extrinsic pathway remains intact — this is why PT is normal in hemophilia. The problem is exclusively within the intrinsic limb, reflected by a prolonged aPTT.

Primary hemostasis (platelet plug formation, vWF, vessel constriction) is also intact — platelet count and bleeding time are normal. This explains why superficial cuts may stop initially but then rebleed, and why deep tissue and joint bleeding — which require a robust fibrin clot — is the clinical hallmark.

Clinical presentation

Hemarthrosis: the hallmark of severe hemophilia

Hemarthrosis — bleeding into joint spaces — is the most characteristic feature of severe hemophilia, occurring in ~75–80% of all bleeding episodes in patients not on prophylaxis. The knees, ankles, and elbows are most commonly affected, with knees accounting for roughly 45% of joint bleeds.

A joint bleed typically presents with:

• Prodrome: warmth, tingling, or a “bubbling” sensation in the joint — patients learn to recognize this
• Rapid swelling as blood accumulates in the synovial space
• Severe pain and loss of range of motion
• Skin color change — the overlying skin becomes warm and taut but rarely shows bruising acutely

Repeated hemarthrosis triggers a destructive inflammatory cycle. Blood in the synovium activates iron-mediated and inflammatory pathways that damage cartilage and bone — hemophilic arthropathy. Repeated joint bleeds over years produce chronic synovitis, progressive cartilage loss, and ultimately a painful, deformed, fused joint. Hemophilic arthropathy is the leading cause of long-term disability in patients with severe hemophilia and the primary rationale for prophylactic factor replacement.

Other bleeding manifestations

Laboratory findings

Laboratory testing in hemophilia has a classic and predictable pattern. Understanding the pattern — and why each test behaves as it does — is essential for both clinical practice and NCLEX preparation.

NCLEX memory tip: In hemophilia, aPTT is prolonged, PT is normal, platelets are normal. The inverse of this pattern (prolonged PT, normal aPTT, normal platelets) suggests an extrinsic pathway problem — warfarin toxicity or factor VII deficiency. In DIC, both PT and aPTT are prolonged with thrombocytopenia — see the DIC nursing reference for comparison. For normal reference ranges across all coagulation studies, consult the nursing lab values cheat sheet.

Treatment

Hemophilia A: desmopressin for mild disease

Desmopressin (DDAVP) is the first-line treatment for mild hemophilia A and some patients with moderate hemophilia A who are having minor procedures. It works by releasing endogenous stores of factor VIII and von Willebrand factor from vascular endothelial cells (Weibel-Palade bodies), transiently raising factor VIII levels by 2–5 fold above baseline.

Key points for nursing:

• Administered IV (0.3 mcg/kg over 15–30 minutes) or intranasally (Stimate nasal spray, 150 mcg per nostril)
• Peak effect occurs 30–90 minutes after IV administration
• Tachyphylaxis develops with repeated doses — stores deplete after 2–3 uses in rapid succession; allow 24–48 hours between doses when possible
• Monitor for water retention and hyponatremia — DDAVP has antidiuretic properties. Restrict fluids; monitor sodium levels especially in young children (at risk for seizures from dilutional hyponatremia)
• Not effective for hemophilia B — factor IX is not stored in endothelial cells; DDAVP has no benefit

A trial dose should be administered before elective procedures to confirm adequate response, as approximately 20% of mild hemophilia A patients are DDAVP non-responders.

Factor replacement: dosing principles

Target factor levels by bleed type (hemophilia A):

• Minor bleed (small joint, minor laceration): target factor VIII 30–50%
• Moderate bleed (large joint, muscle, mouth): target factor VIII 50–80%
• Life-threatening bleed (ICH, retroperitoneal, surgery): target factor VIII 80–100%, sustained for 7–14 days

Prophylaxis

In severe hemophilia, prophylactic factor replacement — administered on a regular schedule, not only after bleeds — is the standard of care. The goal is to maintain trough factor levels above 1–3% to prevent spontaneous bleeds and preserve joint function.

Typical schedules:

• Hemophilia A: factor VIII infusion 2–3 times per week (standard half-life products) or every 3–5 days (extended half-life products)
• Hemophilia B: factor IX infusion 2–3 times per week or once weekly (extended half-life products)

Primary prophylaxis, started in early childhood before the first joint bleed, has dramatically changed the natural history of severe hemophilia and is a key teaching point when counseling families.

Emicizumab (Hemlibra)

Emicizumab is a bispecific monoclonal antibody that bridges activated factor IX and factor X, mimicking the function of the intrinsic tenase complex. It does not contain factor VIII and therefore works even in patients with high-titer factor VIII inhibitors.

Key nursing points:

• Route: subcutaneous injection — significantly simpler for patients than IV factor infusion
• Dosing schedules: loading phase (3 mg/kg weekly × 4 weeks), then maintenance of 1.5 mg/kg weekly, 3 mg/kg every 2 weeks, or 6 mg/kg every 4 weeks — patient preference guides selection
• Approved for: hemophilia A with or without inhibitors
• Monitoring: Standard aPTT-based monitoring is unreliable while on emicizumab — the drug prolongs aPTT even without bleeding. Chromogenic factor VIII assays using bovine reagents are used to measure factor VIII activity in these patients.
• Caution with aPCC: Combining emicizumab with activated prothrombin complex concentrates (FEIBA) has caused serious thromboembolic events and thrombotic microangiopathy. Use aPCC with extreme caution (if at all) in patients on emicizumab; recombinant factor VIIa is the preferred bypassing agent when breakthrough bleeds occur.

Inhibitor development

Approximately 30% of patients with severe hemophilia A and 3–5% with severe hemophilia B develop inhibitors — neutralizing alloantibodies against the infused factor concentrate. Inhibitors render standard factor replacement ineffective and represent the most significant complication in hemophilia management.

Risk factors for inhibitor development include:

• Severe genotype (large deletions, nonsense mutations — the immune system has no prior exposure to the protein)
• Early, intensive factor exposure during bleeding episodes
• African or Latin American ancestry (higher rates vs. Caucasian)
• Positive family history of inhibitors

Inhibitor titers are measured in Bethesda units (BU):

• Low-titer inhibitors (<5 BU): Higher doses of factor concentrate may overcome the inhibitor
• High-titer inhibitors (≥5 BU): Bypassing agents required; immune tolerance induction (ITI) — prolonged high-dose factor VIII administration — may eradicate inhibitors over months to years

Nursing management

Bleeding precautions: core interventions

Joint bleed management: RICE protocol

When a patient with hemophilia reports symptoms of hemarthrosis, the nursing priority is immediate factor replacement (administered as ordered, or calling the physician/hematologist if not yet ordered) combined with the RICE protocol for the affected joint:

• R — Rest: Non-weight bearing; splint or immobilize the joint in a position of comfort. Avoid active range-of-motion exercises during the acute bleed.
• I — Ice: Apply a cold pack (wrapped in cloth to protect skin) for 15–20 minutes every 2 hours. Cold causes vasoconstriction and reduces swelling. Never apply ice directly to skin.
• C — Compression: Gentle elastic bandage wrap to limit swelling — not so tight as to impair circulation.
• E — Elevation: Elevate the affected limb above heart level to reduce venous pressure and limit swelling.

Physical therapy consultation is important after the acute phase resolves to restore range of motion and strengthen muscles supporting the joint.

Pain management

Pain from hemarthrosis is often severe. Management principles:

• Acetaminophen for mild pain
• Opioid analgesics (short-acting) for moderate-to-severe acute joint pain — preferred over NSAIDs
• NSAIDs are contraindicated — their platelet-inhibiting effects worsen bleeding
• COX-2 selective inhibitors (e.g., celecoxib) do not impair platelet function and may be considered for patients with chronic hemophilic arthropathy after hematology consultation — but routine NSAID avoidance is still the safe default teaching
• Aspiration of a tense hemarthrosis (arthrocentesis) is occasionally performed but only after factor replacement and by experienced providers — nursing documentation of swelling progression helps guide this decision

Patient and family education

Hemophilia is a chronic, lifelong condition managed primarily in the outpatient and home setting. Education is one of the highest-impact nursing interventions.

Key teaching content:

• Self-infusion technique — demonstrate IV factor concentrate reconstitution and infusion; return demonstrate; connect to hemophilia treatment center (HTC) for formal training
• Recognition of early bleed signs — especially the prodrome of hemarthrosis (“the warm feeling in my joint”)
• When to go to the emergency department — any head injury, even seemingly minor; signs of intracranial hemorrhage; any bleed uncontrolled after home factor treatment; iliopsoas bleed symptoms
• Medic Alert bracelet — all patients with hemophilia should wear identification stating the diagnosis and factor deficiency type; critical for emergency care if the patient is unconscious
• Medications to avoid — aspirin, NSAIDs (including OTC products); anticoagulants unless prescribed by hematology; herbal supplements with antiplatelet effects (fish oil, vitamin E, ginkgo, garlic supplements)
• Activity and sports guidance — contact sports (football, rugby, boxing, wrestling) are contraindicated in severe hemophilia; swimming, cycling, golf, and walking are generally encouraged; sports decisions individualized with hematology
• School and workplace planning — children need school nurse notification and individualized health plans; adults may need workplace accommodations
• Prophylaxis adherence — emphasize that prophylaxis prevents joint damage and must continue even when feeling well; address barriers (venous access, schedule, cost, insurance)
• Genetic counseling — referral for families with a new diagnosis or for female carriers of childbearing age

Nursing diagnoses

Special populations

Hemophilia in the newborn and infant

• Severe hemophilia may present in the neonatal period with intracranial hemorrhage after vaginal delivery (prolonged pushing increases venous pressure) or bleeding after circumcision
• Delivery planning: parents with known carrier status should notify obstetrics; cesarean section may be recommended for some; vacuum and forceps delivery are generally avoided
• Umbilical cord blood can be tested for factor level at birth
• Vitamin K is administered subcutaneously (not IM) in neonates with suspected or confirmed hemophilia
• Circumcision is deferred until hemophilia status is known; factor replacement required if performed

Hemophilia and surgery

Any patient with hemophilia undergoing surgery — from minor dental extractions to major orthopedic procedures — requires a hemostasis plan developed with hematology prior to the procedure. Nursing responsibilities include:

• Confirming factor product and dose are ordered pre-operatively
• Verifying factor concentrate is available in pharmacy and blood bank before the patient goes to the OR
• Confirming pre-operative factor level has been checked and target achieved
• Post-operative monitoring for delayed bleeding (can occur 24–48 hours after surgery as initial clot is mechanically disrupted)

Hemophilia and chronic pain

Long-standing hemophilic arthropathy produces chronic, often severe joint pain. This population may have a complex pain history with prior opioid exposure. A multidisciplinary approach — hematology, pain management, physical therapy, and potentially addiction medicine — is appropriate. Avoid NSAIDs and aspirin regardless of pain severity.

NCLEX-style practice questions

Question 1. A nurse is caring for a child with severe hemophilia A who is brought to the emergency department after falling from a bicycle. He denies hitting his head but reports knee pain and swelling. His right knee is warm, swollen, and he refuses to bear weight. Which nursing action is the priority?

A) Apply heat to the affected knee to reduce muscle spasm B) Prepare to administer a platelet transfusion C) Administer recombinant factor VIII concentrate as ordered D) Administer ibuprofen 10 mg/kg for pain and inflammation

Answer: C

Rationale: In hemophilia A, joint bleeding requires prompt factor VIII replacement to stop the bleed before joint damage worsens. Option A is incorrect — ice (not heat) is appropriate for hemarthrosis (RICE protocol). Option B is incorrect — hemophilia is a coagulation factor deficiency, not a platelet problem; platelet count is normal. Option D is incorrect and dangerous — NSAIDs inhibit platelet function and worsen bleeding in hemophilia; acetaminophen or opioids are used for pain management.

Question 2. A nurse reviews lab results for a patient with a known bleeding disorder. The aPTT is 78 seconds (normal 25–35 sec), PT is 12 seconds (normal 11–13.5 sec), platelet count is 240,000/µL, and bleeding time is 6 minutes. These findings are most consistent with which condition?

A) Thrombocytopenic purpura B) Hemophilia A or B C) Warfarin toxicity D) Von Willebrand disease type 1

Answer: B

Rationale: Prolonged aPTT with a normal PT, normal platelet count, and normal bleeding time is the classic lab pattern of hemophilia A or B — intrinsic pathway factor deficiency with intact primary hemostasis and intact extrinsic pathway. Option A (thrombocytopenia) would show a low platelet count with prolonged bleeding time. Option C (warfarin toxicity) prolongs PT (and INR) — warfarin inhibits vitamin K-dependent factors in the extrinsic and common pathways. Option D (vWD type 1) typically shows a prolonged bleeding time with possible mild aPTT elevation and low vWF level, but the pattern is not as isolated to the aPTT. For comparison of bleeding disorder lab patterns, see the thrombocytopenia nursing reference.

Question 3. A nurse is educating a family about home management of their child’s newly diagnosed moderate hemophilia A. Which statement by the parent indicates the teaching has been effective?

A) “We should avoid all physical activity since exercise can trigger joint bleeds.” B) “If our child gets a small cut, we will apply pressure and monitor at home, but any head injury — even minor — requires an emergency room visit.” C) “We can give ibuprofen for pain after joint bleeds since it will reduce the inflammation.” D) “Desmopressin is used to treat joint bleeds in severe hemophilia.”

Answer: B

Rationale: Any head injury in a patient with hemophilia requires emergent evaluation, even if the injury appears minor — intracranial hemorrhage can be catastrophic and must be ruled out. Option A is incorrect — moderate exercise (swimming, cycling) is encouraged; contact sports are restricted in severe disease, not all activity. Option C is incorrect — NSAIDs worsen bleeding in hemophilia by inhibiting platelet function; acetaminophen or opioids are appropriate. Option D is incorrect — desmopressin is used in mild hemophilia A (and some moderate cases) to release endogenous factor VIII stores; it is not used for severe hemophilia A (stores are insufficient) and is ineffective for hemophilia B.

Question 4. A patient with severe hemophilia A is receiving recombinant factor VIII concentrate for a knee hemarthrosis. Four hours after the infusion, the patient reports that the knee pain is worse rather than better, and the nurse notes the swelling has increased. Which complication should the nurse suspect and report to the provider?

A) Anaphylactic reaction to the factor concentrate B) Development of a factor VIII inhibitor C) Incorrect factor IX product administered in error D) Normal post-infusion inflammatory response

Answer: B

Rationale: Failure of factor replacement to produce the expected clinical improvement raises strong suspicion for a factor VIII inhibitor — a neutralizing antibody that inactivates infused factor VIII before it can exert its effect. This occurs in approximately 30% of patients with severe hemophilia A. The nurse should report this immediately; a Bethesda inhibitor assay will be ordered, and management will shift to bypassing agents (aPCC, recombinant factor VIIa) or emicizumab. Option A (anaphylaxis) would present with systemic signs — urticaria, bronchospasm, hypotension — not simply failure to respond to factor. Option C is unlikely if the five rights of medication administration were followed. Option D is incorrect — hemarthrosis should respond to adequate factor replacement within hours.

Question 5. A nurse is preparing to administer desmopressin (DDAVP) intravenously to a patient with mild hemophilia A prior to a dental extraction. Which assessment finding requires the nurse to hold the medication and consult with the provider?

A) Blood pressure 122/78 mmHg B) Serum sodium 128 mEq/L C) Factor VIII level 12% D) Heart rate 88 beats per minute

Answer: B

Rationale: DDAVP has significant antidiuretic (ADH-like) effects that cause water retention and can produce or worsen hyponatremia. A serum sodium of 128 mEq/L represents moderate hyponatremia (normal 135–145 mEq/L). Administering DDAVP in this setting risks worsening hyponatremia to a level that causes seizures, especially in children and elderly patients. The nurse should hold the medication and notify the provider. Options A and D are within normal limits and do not affect DDAVP administration. Option C (factor VIII 12%) would indicate mild hemophilia A — DDAVP is appropriate for this severity range, so the factor level itself is not a reason to hold the medication. For a review of sodium and other electrolyte management, see the electrolyte imbalances reference.

Question 6. Which intervention is most important for the nurse to implement when caring for a patient with hemophilia B who requires a laboratory blood draw?

A) Request an arterial blood draw from the radial artery for more accurate laboratory values B) Apply pressure to the venipuncture site for at least 5–10 minutes after the draw C) Administer recombinant factor IX one hour before drawing blood D) Use a 16-gauge needle to minimize the number of puncture attempts

Answer: B

Rationale: In hemophilia B (factor IX deficiency), the intrinsic coagulation pathway is impaired and clot formation at venipuncture sites is significantly delayed. Standard 1–2 minutes of pressure is inadequate — at least 5–10 minutes of continuous direct pressure is required, with the site checked and re-pressured as needed before leaving the patient. Option A is incorrect and harmful — arterial punctures are invasive and higher-risk bleeding sites; they should be avoided in hemophilia. Option C is incorrect — routine phlebotomy does not require pre-treatment with factor IX; factor replacement is reserved for significant bleeding events or procedures (surgery, joint aspiration). Option D is incorrect — a smaller gauge needle (21–23 gauge) is preferred to minimize tissue trauma, not a larger one.

Related nursing references

This article is part of the hematology cluster. For related content:

• Sickle cell disease nursing — another X-linked hematologic disorder with distinct crisis patterns and nursing priorities
• Anemia nursing reference — classification, lab findings, and management across anemia types; hemolytic anemia from factor replacement reactions covered
• DIC nursing reference — disseminated intravascular coagulation; contrast lab patterns (DIC: both PT and aPTT prolonged + thrombocytopenia vs hemophilia: aPTT prolonged only)
• Thrombocytopenia nursing reference — ITP, HIT, TTP; differentiate platelet-based bleeding from factor-based bleeding
• Nursing lab values cheat sheet — coagulation studies reference ranges: aPTT, PT, INR, bleeding time, platelet count, fibrinogen
• Electrolyte imbalances reference — includes hyponatremia management, relevant for DDAVP monitoring
• GI bleed nursing reference — upper and lower GI bleeding assessment; relevant when hemophilia patients present with GI hemorrhage
• DVT nursing — venous thromboembolism; relevant for context when hemophilia patients on emicizumab or aPCC are at risk for thrombosis